Introduction: The incidence of Hodgkin lymphoma (HL) shows a clear bimodal distribution with the first peak in young adults and the second peak in the elderly. Treatment—usually with combination chemotherapy (CT) and/or radiotherapy (RT)—has resulted in high survival rates compared to other cancers, even in patients with advanced disease. However, many patients experience long-term health problems due to therapy-related side effects, which may impact on their quality of life (QoL). Methods: A literature search was conducted in MEDLINE, EMBASE, and the Cochrane Library (accessed July 29th). The scope of the systematic review (SR) included the identification of studies reporting on clinical outcomes, resource use, and QoL (patients and caregivers). Publications reporting on QoL in patients with advanced disease are the focus of the current publication. Results: Ten publications reporting on QoL were identified. The majority of studies were cross-sectional, cohort studies, and included HL survivors (mean age, 35-47 years) who had been treated with combination CT with or without RT and were no longer receiving treatment for their disease. Five publications were from one group in the US (N = 273 patients), who found that, using a range of measures evaluating current psychosocial adaptation, HL survivors (mean, 6.3-y posttreatment) were at an increased risk of psychological distress, sexual problems, infertility, and additional treatment- and disease-related medical problems. The other studies, which included three from the Netherlands (N = 43-180 across studies) and one each from Germany (N = 126) and Austria (N = 98), used the cancer-specific EORTC-QLQ-C30 questionnaire, among others. EORTC-QLQ-C30 scores were significantly worse in HL survivors (mean > 4.5 y posttreatment across studies) compared to historical control populations across a number of functioning domains (role, emotional, cognitive, and social), together with elevated levels of fatigue, dyspnoea, and diarrhoea. Dyspnoea was also significantly worse in HL survivors who had been treated with high dose carmustine-containing regimens vs conventional CT (various regimens). Dyspnoea and diarrhoea may be due to the long-term effects of CT-induced pulmonary toxicity (eg, from bleomycin or high dose carmustine) and gastrointestinal toxicity (eg, anthracyclines, bleomycin, or the vinca-alkaloids). In addition, there were significantly higher rates of dyspnoea, pain, and fatigue and worse physical functioning in patients treated with both CT/RT compared with those treated with either RT or CT alone, which may be due to cumulative toxicities of CT and RT. Conclusions: Many HL survivors experience a substantial adverse impact on their QoL, even many years after curative treatment. New treatment regimens that have fewer side-effects are needed to improve the long-term health and QoL of patients with advanced HL. Keywords: Hodgkin lymphoma (HL)